Structure-based phenotyping predicts HIV-1 protease inhibitor resistance

Protein Science

Volumn 12, Issue 8, 2003, Pages 1706-1718

  Shenderovich, Mark D ^a   Kagan, Ron M ^b   Heseltine, Peter N R ^b   Ramnarayan, Kal ^a  

^a Cengent Therapeutics Inc   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

Binding energy; Drug resistance; HIV protease inhibitors; Molecular modeling; Structure based phenotyping

Indexed keywords

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ALGORITHM; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG EFFECT; DRUG TARGETING; ENZYMOLOGY; GENE MUTATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

ALGORITHMS; ANTI-HIV AGENTS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; MODELS, MOLECULAR; PHENOTYPE; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0041341885     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1110/ps.0301103     Document Type: Article

References (52)

1. Abagyan, R. and Totrov, M. 1994. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J. Mol. Biol. 235: 983-1002.
2. Abagyan, R.A., Totrov, M., and Kuznetsov, D. 1994. ICM - a new method for protein modeling and design: Applications to docking and structure prediction from the disordered native conformation. J. Comput. Chem. 15: 488-506.
3. Baldwin, E.T., Bhat, T.N., Liu, B., Pattabiraman, N., and Erickson, J.W. 1995. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. Nat. Struct. Biol. 2: 244-249.
4. Baxter, J.D., Mayers, D.L., Wentworth, D.N., Neaton, J.D., Hoover, M.L., Winters, M.A., Mannheimer, S.B., Thompson, M.A., Abrams, D.I., Brizz, B.J., et al. 2000. A randomized study of antiretroviral management based on plasma genotypic retroviral resistance testing in patients failing therapy. AIDS 14: F83-93.
5. Carpenter, C.C., Cooper, D.A., Fischl, M.A., Gatell, J.M., Gazzard, B.G., Hammer, S.M., Hirsch, M.S., Jacobsen, D.M., Katzenstein, D.A., Montaner, J.S., et al. 2000. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel. JAMA 283: 381-390.
6. Carrillo, A., Stewart, K.D., Sham, H.L., Norbeck, D.W., Kohlbrenner, W.E., Leonard, J.M., Kempf, D.J., and Molla, A. 1998. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-387, a novel protease inhibitor. J. Virol. 72: 7532-7541.
7. Cohen, C., Hunt, S., Sension, M., Farthing, C., Conant, M., Jacobson, S., Nadler, J., Verbiest, W., Hertogs, K., Amesi, M., et al. 2002. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16: 1-10.
8. th International Workshop on HIV Drug Resistance & Treatment Strategies. Scottsdale, AZ, poster # 158.
9. Dominy, B.N. and Brooks III, C.L. 1999. Methodology for protein ligand binding studies: Application to a model for drug resistance, the HIV/FIV protease system. Proteins 36: 318-331.
10. Fleiss, J.L. 1981. Statistical methods for rates and proportions, 2nd ed., pp. 38-46. John Wiley, New York.
11. Gasteiger, J. and Marsili, M. 1980. Iterative partial equalization of orbital electronegativities: A rapid access to atomic charges. Tetrahedron 36: 3219-3228.
12. Gulnik, S.V., Suvorov, L.I., Liu, B., Yu, B., Anderson, B., Mitsuya, H., and Erickson, J.W. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34: 9282-9287.
13. Gulnik, S., Erickson, J.W., and Xie, D. 2000. HIV protease: Enzyme function and drug resistance. Vitam. Horm. 58: 213-256.
14. Haubrich, R.H., Currier, J.S., Forthal, D.N., Beall, G., Kemper, C.A., Johnson, D., Dube, M.P., Hwang, J., Leedom, J.M., Tilles, J., et al. 2001. A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. Clin. Infect. Dis. 33: 1060-1068.
15. Hertogs, K., de Bethune, M.-P., Miller, V., Ivens, T., Schel, P., van Cauwenberge, A., van den Eynde, C., van Gerwen, V., Azin, H., van Houtte, M., et al. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42: 269-276.
16. Hirsch, M.S., Brun-Vezinet, F., D'Aquila, R.T., Hammer, S.M., Johnson, V.A., Kuritzkes, D.R., Loveday, C., Mellors, J.W., Clotet, B., Conway, B., et al. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. JAMA 283: 2417-2426.
17. Holloway, M.K., Wai, J.M., Halgren, T.A., Fitzgerald, P.M.D., Vacca, J.R., Dorsey, B.D., Levin, R.B., Thompson, W.J., Chen, L.J., deSolms, S.J., et al. 1995. A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. J. Med. Chem. 38: 305-317.
18. Hong, L., Zhang, X.C., Hartsuck, J.A., and Tang, J. 2000. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insight into the mechanisms of drug resistance. Protein Sci. 9: 1898-1904.
19. King, N.M., Melnick, L., Prabu-Jeyabalan, M., Nalivaika, E., Yang, S.-S., Gao, Y., Zepp, C., Heefner, D.D., and Schiffer, C.A. 2002. Lack of synergy for inhibitor targeting a multi-drug-resistant HIV-1 protease. Protein Sci. 11: 418-429.
20. Klabe, R.M., Bachler, L.T., Ala, P.J., Erickson-Viitanen, S., and Meek, J.L. 1998. Resistance to HIV protease inhibitors: A comparison of enzyme inhibition and antiviral potency. Biochemistry 37: 8735-8742.
21. Kohl, N.E., Emini, E.A., Schleif, W.A., Davis, L.J., Heimbach, J.C., Dixon, R.A., Scolnick, E.M., and Sigal, I.S. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. 85: 4686-4690.
22. Maggio, E.T. and Ramnarayan, K. 2001. Recent developments in computational proteomics. Trends Biotechnol. 19: 266-272.
23. Maggio, E.T., Shenderovich, M., Kagan, R., Goddette, D., and Ramnarayan, K. 2002. Structural pharmacogenomics, drug resistance and design of antiinfective super-drugs. Drug Discov. Today 7: 1214-1220.
24. Mahalingam, B., Louis, J.M., Hung, J., Harrison, R., and Weber, I.T. 2001. Structural implications of drug-resistant mutations of HIV-1 protease: Highresolution crystal structures of the mutant protease/substrate analogue complexes. Proteins 43: 455-464.
25. Maiorov, V. and Abagyan, R. 1998. Energy strain in three-dimensional protein structures. Fold. Des. 3: 259-269.
26. Markland, W., Rao, B.G., Parsons, J.D., Black, J., Zuchowski, L., Tisdale, M., and Tung, R. 2000. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir. J. Virol. 74: 7636-7641.
27. Markowitz, M., Mo, H., Kempf, D.J., Norbeck, D.W., Bhat, T.N., Erickson, J.W., and Ho, D.D. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69: 701-706.
28. Maschera, B., Darby, G., Palu, G., Wright, L., Tisdale, M., Myers, R., Blair, E.D., and Furfine, E.S. 1996. Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J. Biol. Chem. 271: 33231-33235.
29. McCarric, M.A. and Kollman, P.A. 1999. Predicting relative binding affinities of non-peptide HIV protease inhibitors with free energy perturbation calculations. J. Comput. Aided Mol. Dev. 13: 109-121.
30. Molsoft, LLC. 1999. ICM 2.7 program manual. MolSoft, San Diego, CA.
31. Nair, A.C., Jayatilleke, P., Wang, X., Miertus, S., and Welsh, W.J. 2002. Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: Improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor- and receptor-based properties. J. Med. Chem. 45: 973-983.
32. Némethy, G., Gibson, K.D., Palmer, K.A., Yoong, C.N., Paterlini, G., Zagari, A., Rumsey, S., and Scheraga, H.A. 1992. Energy parameters in polypeptides. 10. Improved geometrical parameters and nonbonded interactions for use in the ECEPP/3 algorithm, with application to proline-containing peptides. J. Phys. Chem. 96: 6472-6484.
33. Palella Jr., F.J., Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., Aschman, D.J., and Holmberg, S.D. 1998. Declining morbid ity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338: 853-860.
34. Partaledis, J.A., Yamaguchi, K., Tisdale, M., Blair, E., Falcione, C., Maschera, B., Myers, R.E., Pazhanisamy, S., Futer, O., Cullinan, A.B., et al. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69: 5228-5235.
35. Patick, A.K., Mo, H., Markowitz, M., Appelt, K., Wu, B., Musick, L., Kalish, V., Kaldor, S., Reich, S., Ho, D., et al. 1996. Antiviral resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40: 292-297.
36. Pazhanisamy, S., Stuver, C.M., Cullinan, A.B., Margolin, N., and Rao, B.G. 1996. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J. Biol. Chem. 271: 17979-17985.
37. Perez, C., Pastor, M., Ortiz, A.R., and Gago, F. 1998. Comparative binding energy analysis of HIV-1 protease inhibitors: Incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. J. Med. Chem. 41: 836-852.
38. Petropoulos, C.J., Parkin, N.T., Limoli, K.L., Lie, Y.S., Wrin, T., Huang, W., Tiai, H.; Smith, D., Winslow, G.A., Capon, D.J., et al. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44: 920-928.
39. Qari, S.H., Respess, R., Weinstock, H., Beltrami, E.M., Hertogs, K., Larder, B.A., Petropoulos, C.J., Hellmann, N., and Heneine, W. 2002. Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J. Clin. Microbiol. 40: 31-35.
40. Schapira, M., Totrov, M., and Abagyan, R. 1999. Prediction of the binding energy for small molecules, peptides and proteins. J. Mol. Recognit. 12: 177-186.
41. Schinazi, R.F., Larder, B.A., and Mellors, J.W. 2000. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. International Antiviral News 8: 65-91.
42. Schock, H.B., Garsky, V.M., and Kuo, L.C. 1996. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J. Biol. Chem. 271: 31957-31967.
43. Shafer, R.W. 2002. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 15: 247-277.
44. Shenderovich, M., Ramnarayan, K., Kagan, R., and Hess, P. 2001a. Structural pharmacogenomics approach to the evaluation of drug resistant mutations in HIV-1 protease. J. Clin. Ligand Assay 24: 140-144.
45. Shenderovich, M.D., Tseitin, V., Fisher, C.L., and Ramnarayan, K. 2001b. Molecular modeling and binding energy calculations for drug resistant mutations in HIV-1 protease-inhibitor complexes. In Peptides: The wave of the future. Proceedings of the 2nd International and the 17th American Peptide Symposium (eds. M. Lebl and R.A. Houghten), pp. 418-419. American Peptide Society, San Diego, CA.
46. Stoll, V., Qin, W., Stewart, K.D., Jakob, C., Park, C., Walter, K., Simmer, R.L., Helfrich, R., Bussiere, D., Kao, J., et al. 2002. X-ray crystallographic structure of ABT-378 (Lopinavir) bound to HIV-1 protease. Bioorg. Med. Chem. 10: 2803-2806.
47. Tomasselli, A.G. and Heinrikson, R.L. 2000. Targeting the HIV-protease in AIDS therapy: A current clinical perspective. Biochim. Biophys. Acta 1477: 189-214.
48. Totrov, M. and Abagyan, R. 2001. Rapid boundary element solvation electrostatics calculations in folding simulations: Successful folding of a 23-residue peptide. Biopolymers 60: 124-133.
49. Wang, W. and Kollman, P.A. 2001. Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance. Proc. Natl. Acad. Sci. 98: 14937-14942.
50. Weber, I. and Harrison, R.W. 1999. Molecular mechanics analysis of drug-resistant mutants of HIV protease. Protein Eng. 12: 469-474.
51. Wlodawer, A. and Vondrasek, J. 1998. Inhibitors of HIV-1 protease: A major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27: 285-327.
52. Xie, D., Gulnik, S., Gustchina, E., Yu, B., Shao, W., Qoronfleh, W., Nathan, A., and Erickson, J.W. 1999. Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pH. Protein Sci. 8: 1702-1707.